Similarly, Dupilumab, an anti‐IL‐4Rα IgG4 monoclonal antibody undergoing review evaluation for atopic dermatitis, Galcanezumab an IgG4 antibody targeting calcitonin gene‐related peptide, being studied for use in patients with severe migraines, and Fasinumab, an IgG4 mAb targeting nerve growth factor 129, being evaluated in phase 3 clinical studies as a treatment for osteoarthritis pain, owe their probably action to direct interference with the action of the target protein and not immunomodulation. Here, IL4R is linked to atopic eczema.